(Q35847482)

English

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

scientific article published on 30 November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Clara D. Bloomfield

9

object named as

Clara D Bloomfield

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

Richard A. Larson

10

object named as

Richard A Larson

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Charles A Schiffer

11

object named as

Charles A Schiffer

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

Bayard L Powell

5

object named as

Bayard L Powell

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

Philip C Amrein

4

object named as

Philip C Amrein

1 reference

Europe PubMed Central

10 August 2017

PMC publication ID

author name string

Joseph O Moore

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Stephen L George

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Richard K Dodge

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Jonathan E Kolitz

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Maria R Baer

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Frederick R Davey

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

30 November 2004

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

105

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

3420-3427

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Therapeutic options for acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Nonparametric confidence limits for survival probabilities and median survival time.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

11 July 2018

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

24 September 2018

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

24 September 2018

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

24 September 2018

Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1895015

24 September 2018

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

https://pubmed.ncbi.nlm.nih.gov/15572587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15572587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15572587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conditional power calculations as an aid in the decision whether to continue a clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15572587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B

1 reference

https://pubmed.ncbi.nlm.nih.gov/15572587

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2004-08-2977

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35847482&oldid=2118322477"